http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1405910-A4
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3658808b82c59b5c52696ca74f1f7de9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6424 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 |
| filingDate | 2002-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fa4627a9716171c543ef196c2b77c9e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eeaf4a57f1159244e3c88dae8a0414e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7731f2893c85391d629e4b685b0bea20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b3a9d9008107689e784354a5cc2ff99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90f9f698e79aeffbce8cae9d4b96af43 |
| publicationDate | 2005-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1405910-A4 |
| titleOfInvention | PROCESS RELATING TO THE PRODUCTION OF HUMAN THROMBIN BY GENE MODIFICATION |
| abstract | A genetically modified thrombin which is efficiently produced with the use of a gene modification technique which comprises: 1) the step wherein a transformant constructed by transforming an animal cell with an expression vector carrying a gene encoding prethrombin integrated into the downstream of a promoter is cultured and the prethrombin thus produced and accumulated in the culture medium is collected; 2) the step wherein the human prethrombin-containing solution thus collected and recovered is activated by treating with ecarin to thereby convert into human thrombin; and 3) the step wherein purified human thrombin is obtained from the liquid reaction mixture having been inactivated as described above. Thus, human thrombin can be provided in a large amount at a high safety and a low cost while minimizing the effects of blood-origin components. |
| priorityDate | 2001-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.